Tokyo, Nov. 6 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059645) titled 'Effect of SGLT2 Inhibitors on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: A Study Using an Medical Record Database' on Nov. 5.
Study Type:
Others,meta-analysis etc
Primary Sponsor:
Institute - National Institute for Health Security
Condition:
Condition - type 2 diabetes, Non-Alcoholic Fatty Liver Disease
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To clarify the effect of SGLT2 inhibitors on non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes using a nationwide diabetes database directly linked to electronic medical records
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients with type 2 diabetes who newly initiated treatment with SGLT2 inhibitors or other oral antidiabetic drugs and continued the therapy for more than three years
Key exclusion criteria - Patients treated with pioglitazone or GLP-1 receptor agonists
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2022 Year 08 Month 08 Day
Date of IRB - 2022 Year 08 Month 08 Day
Anticipated trial start date - 2025 Year 11 Month 05 Day
Last follow-up date - 2026 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068217
Disclaimer: Curated by HT Syndication.
